Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Christopher Aderman (NPI 1912260381)

Field	Value
Entity Type	Individual
Organization	Christopher Aderman
Address	24601 Se Stark St
City	Troutdale
State	OR
ZIP	97060
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	June 20, 2012

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

CHRISTOPHER ADERMAN is a Retina Specialist (Ophthalmology) Physician with an NPI enumerated 2012-06-20, indicating roughly 14 years of Medicare enrollment and sustained practice presence in TROUTDALE, OR. The provider's lifetime Medicare revenue totals $2.2M, with no Medicaid billing on file, making this essentially a single-payer (Medicare-focused) billing profile.

Revenue is highly concentrated in intravitreal drug administration: the top three Medicare revenue codes (J0178, J2777, 67028) together account for 75.4% of total Medicare revenue, signaling that anti-VEGF and related intravitreal injections plus isolated vitreous injections are the core service line driving payments. This mix is consistent with a retina practice focused on pharmacologic management of retinal disease rather than a general ophthalmology outpatient mix.

J0178 (aflibercept) is the dominant single code, generating $1.2M and representing 52.2% of the provider's Medicare revenue; nationally the provider ranks #692 of 3204 (78th percentile), which places their aflibercept volume in the typical-to-above-typical range but not among the highest-volume specialists. High reliance on a single high-cost drug code suggests drug procurement and administration are central operational and revenue considerations for the practice.

J2777 (faricimab-svoa) and 67028 (isolated intravitreal injection) are the second and third largest contributors ($358.4K and $161K respectively), further underscoring an injection-heavy service mix. The J2777 rank (#851 of 2039, 58th percentile) is typical, while 67028 ranks #731 of 4255 (83rd percentile), indicating above-typical use of the injection procedure relative to national peers and supporting the characterization of a procedure-driven retina practice.

Several ancillary service codes show notable deviations from typical national volumes: 92134 (retinal imaging) has 2.1K claims and $70.3K revenue and ranks in the 97th percentile (notably above typical national volume), suggesting the provider performs a high volume of retinal diagnostic imaging to support injection-based care. Likewise, 99213 office E/M visits rank in the 98th percentile (extreme outlier), indicating very high outpatient visit volume relative to national peers, which may reflect frequent follow-up and monitoring typical for retina treatment protocols.

Although many drug and procedure codes are in typical percentiles, some drug-related codes show concentrated usage: J3490 (unclassified drugs) contributes $138.1K (6.2% of Medicare revenue) and ranks in the 71st percentile, while J2781 (pegcetacoplan) and Q5124 (ranibizumab biosimilar) together add meaningful revenue shares (3.7% and 3.4% respectively). This pattern shows the practice uses a mix of labeled biologics and unclassified/compounded products, which has implications for drug sourcing, billing oversight, and inventory management.

The absence of any Medicaid billing (none below) means the provider’s public-payer exposure is concentrated entirely in Medicare; payer mix risk or opportunity regarding Medicaid-managed care is not evident from the data. Any network or contracting assessments should treat this profile as Medicare-centric unless additional non-public claims data indicate broader payer engagement.

From a competitive standpoint, the provider is a meaningful regional participant for certain retina services: high percentile ranks on retinal imaging (92134) and office visit E/M (99213) indicate unusually high utilization compared with national peers, while drug-administration volumes for flagship biologics are solidly within typical national ranges rather than dominant top-tier volumes. Combined, these signals point to a practice with an intensive follow-up and imaging workflow that supports high-frequency intravitreal therapy as its primary business model.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

16 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,690	$690	$1.2M
J2777	Injection, faricimab‑svoa, 0.1 mg	12,360	$30	$358.4K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,560	$100	$161K
J3490	Unclassified drugs	100	$1,410	$138.1K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	690	$120	$83.2K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	490	$160	$75.7K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,130	$30	$70.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	900	$70	$61.5K
J7999	Compounded drug, not otherwise classified	680	$70	$48.5K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	290	$90	$25.3K

Showing 1–10 of 16

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

Christopher Aderman — 2 of 16 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

16 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	9	60	840	$680	$623.7K
J2777	15	30	10,050	$30	$527.6K
J2781	6	10	690	$120	$102.6K
Q5124	1	10	490	$160	$75.9K
67028	8	70	580	$90	$72.3K
J3490	12	50	40	$640	$42.9K
67042	10	10	20	$1,100	$27.5K
J7999	9	50	270	$70	$23.4K
92014	111	440	110	$80	$16K
92235	10	30	60	$100	$11.1K

Showing 1–10 of 16

Related Providers

Other providers that share a Tax Identification Number (TIN) with Christopher Aderman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Eye Health Northwest, PC	OR	Ophthalmology Physician	$0	$15.7M
Stephen Davis	AR	Retina Specialist (Ophthalmology) Physician	$2.5M	$4.7K
Elizabeth Verner-cole	OR	Retina Specialist (Ophthalmology) Physician	$1.7M	$0
Jonathan Yoken	OR	Retina Specialist (Ophthalmology) Physician	$1.5M	$0
Brian Chan-kai	OR	Retina Specialist (Ophthalmology) Physician	$1.3M	$0
Joseph Simonett	OR	Ophthalmology Physician	$532.6K	$0
Christopher Kirkpatrick	WI	Ophthalmology Physician	$288.6K	$0
David Sanders	OR	Ophthalmology Physician	$229.6K	$0
Jonathan Kemp	OR	Ophthalmology Physician	$221.9K	$0
Shane Kim	OR	Ophthalmology Physician	$191.1K	$0

Christopher Aderman — Billing Profile & Reimbursement Data

Sign up for Christopher Aderman — Billing Profile & Reimbursement Data policy alerts

Christopher Aderman — Billing Profile & Reimbursement Data

Sign up for Christopher Aderman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Frequently Asked Questions

References